A baby born in a neonatal intensive care unit in sub-Saharan Africa develops a fever at 36 hours of life. The clinician suspects sepsis. There is no point-of-care diagnostic available — none exists anywhere in the world that can identify the pathogen from a neonatal blood sample at bedside. A blood culture is drawn, if the lab can process it. Results will take 48 to 72 hours. Every hour of delayed appropriate treatment increases the risk of death by 7.6 percent.
The clinician starts the WHO-recommended empiric regimen: ampicillin plus gentamicin. According to the largest study ever conducted on neonatal sepsis in low- and middle-income countries, this regimen will fail against 71.5 percent of Gram-negative infections the baby might have.
That baby — and the 3 million others like them who develop sepsis each year — exists at the intersection of every failure this blog has documented: broken diagnostics, an empty pipeline, stalled governance, and a market that has decided newborns in poor countries are not worth investing in.
Today — April 8, 2026 — CARB-X opens its 2026 funding round with two explicit neonatal sepsis themes: non-vaccine prevention and rapid diagnostics. It is the largest coordinated investment call ever specifically targeting neonatal AMR. This article maps the crisis it's trying to solve.
The Numbers Behind the Silence
Neonatal sepsis is the third leading cause of newborn death worldwide. The numbers are staggering and underreported:
One in five global AMR deaths is a neonate. Yet the WHO's Global Action Plan on AMR — currently being updated for 2026-2035 — does not contain a dedicated section on children or newborns. GARDP has explicitly criticized this omission.
The Regimen That Fails
The BARNARDS study — 36,285 neonates across seven LMICs — remains the definitive dataset on what's killing these babies and whether our drugs work. The findings are devastating:
The dominant pathogen is Klebsiella pneumoniae — the convergent superbug I profiled in Post #16. In NICU outbreaks, CRKP carries a 37.9% mortality rate in neonates. Premature infants face over 40% mortality. These are the most vulnerable patients on earth facing the most resistant pathogen with the least appropriate tools.
The Diagnostic Void
There is no rapid point-of-care neonatal sepsis diagnostic available anywhere in the world.
That sentence should be read again. In 2026 — when we can sequence a genome in hours and diagnose COVID from a nasal swab in minutes — we cannot tell a clinician in a neonatal ward whether a sick baby has a bacterial infection, what organism it is, or which antibiotics will work, without waiting two to three days for a blood culture that may never be processed.
The INSIGHTS survey of neonatal clinicians across sub-Saharan Africa quantified the void:
The NeoTest initiative, chaired by Lord Jim O'Neill (author of the landmark 2016 AMR Review), is attempting to solve this through an advance market commitment modeled on the $1.5 billion pneumococcal AMC that saved an estimated 700,000 lives. The concept: commit funding in advance so that companies developing neonatal sepsis diagnostics know there will be a market for affordable products in LMICs.
CARB-X has already funded three neonatal diagnostic programs:
| Program | Technology | Funding | Time to Result |
|---|---|---|---|
| Melio | Microfluidic + acoustic + molecular + AI | $3.5M | ~3 hours |
| AstraDx | Digital imaging + signal processing | $3.0M | ~4 hours |
| QuantaMatrix (dRAST) | Agarose-based rapid AST, adapted for neonatal volumes | $2.85M | ~6 hours |
Today's CARB-X call explicitly seeks more: rapid, low-complexity triage diagnostics with small sample volumes — the critical constraint for neonates, whose blood draws are limited to fractions of a milliliter.
The Treatment Desert
Even when clinicians know what pathogen they're fighting, the weapons may not exist.
The AMR Benchmark 2026 found that of 35 antibiotic R&D projects in the pipeline, only five include pediatric development plans. In 17 sub-Saharan African countries, zero pediatric antibiotic formulations are registered for resistant infections. Not limited availability — literally zero.
This is why GARDP's NeoSep1 trial matters so much. It is the first randomized controlled trial ever designed specifically to find better antibiotic combinations for drug-resistant neonatal sepsis. The approach is pragmatic rather than novel: three combinations of existing off-patent antibiotics — fosfomycin-amikacin, flomoxef-amikacin, and flomoxef-fosfomycin — tested against the WHO standard and five other regimens.
Part 1 results (AAC, February 2026): fosfomycin and flomoxef are pharmacokinetically safe in neonates at standard doses. Sixty-five preterm and term newborns across South Africa and Kenya tolerated both drugs well. Part 2, now expanded to nine countries with a target of 3,000 newborns, launched in mid-2025. Results expected by 2028.
Three thousand newborns. Nine countries. Three years. To answer a question — what antibiotics should we give a septic baby? — that the current system failed to address for decades.
The Prevention Frontier
If treatment options are thin and diagnostics absent, prevention becomes the critical lever. Two approaches are converging:
Maternal Vaccination
Klebsiella pneumoniae is the dominant neonatal sepsis pathogen in LMICs. A maternal vaccine that generates protective antibodies transferred to the baby during pregnancy could prevent infections before they start.
The science is further along than most people realize:
Tetravalent O-antigen bioconjugate vaccine (O1v1/O2a/O2afg/O3b). 166 healthy adults (J Infectious Diseases, Feb 2026). Statistically significant IgG increases for all four serotypes (P<0.001). Well tolerated. First K. pneumoniae conjugate vaccine to reach clinical testing. Projected 70% strain coverage worldwide.
Bivalent K1/K2 glycoconjugate vaccine targeting capsular serotypes. 20 healthy adults. Preliminary data shows immunogenic and safe.
Stanton, Keegan, Wyres & Holt analyzed 1,930 neonatal blood isolates from 35 sites across 13 countries. A 20-valent K-antigen vaccine could cover 72.9% of neonatal strains. A 10-valent O-antigen vaccine: ~99%. The raw materials for a neonatal K. pneumoniae vaccine are mapped. Economic modeling (Phil Trans Royal Society B, Feb 2026): $6.9 billion in avertable DALYs per year across 107 LMICs.
These are vaccines, not CARB-X's current scope (which explicitly focuses on non-vaccine prevention). But they represent the most advanced biological intervention against the dominant neonatal sepsis pathogen. A maternal K. pneumoniae vaccine that works would reshape the crisis.
Infection Prevention
CARB-X's April 8 call specifically seeks non-vaccine preventive approaches — innovations like decolonization, microbiome protection, or novel IPC interventions for neonatal settings.
A Zambian NICU study (PLOS Global Public Health, 2026) tested a low-cost IPC bundle: alcohol hand rub, enhanced surface cleaning, chlorhexidine bathing, staff training with SMS reminders. It temporarily disrupted an MDR K. pneumoniae outbreak — mortality dropped during the intervention period. But strains reemerged. Roughly 35% of infections occurred within 24-48 hours of admission, suggesting contaminated environmental sources that basic IPC cannot eliminate.
This is the prevention paradox: low-cost interventions can reduce but not eliminate hospital-acquired neonatal sepsis. Novel biological prevention tools — whether decolonization agents, engineered probiotics, or monoclonal antibodies — are what CARB-X is now seeking.
The Compound Failure
What makes neonatal sepsis in LMICs so lethal is not any single gap. It is the compound failure — every system failing simultaneously for the same patients.
A baby born today in Nairobi or Dhaka with sepsis faces: no test to identify the pathogen, a first-line regimen that probably won't work, no age-appropriate second-line drugs registered in the country, no vaccine to have prevented the infection, and a 7.6% increase in death risk for every hour the system takes to figure this out.
What CARB-X Is Asking For
The funding round that opens today has four themes. Two are neonatal:
Non-vaccine approaches to prevent neonatal sepsis caused by at least one of four target pathogens: A. baumannii, E. coli, K. pneumoniae, or S. aureus. Administration to pregnant women and neonates is in scope. This could include decolonization strategies, monoclonal antibodies, microbiome interventions, or novel IPC technologies.
Rapid, low-complexity triage diagnostics to support neonatal sepsis care. Key criteria: time-to-result, cost-of-goods, and small sample volumes — the critical constraint in neonatal blood draws. The goal is to break the 48-72 hour diagnostic delay that kills.
Expressions of interest are open from today through April 22. Webinars on April 9 and 10 will detail the scope. A second funding call in Q4 2026 will continue the same themes.
This is, to my knowledge, the most concentrated investment effort ever directed specifically at neonatal AMR. It comes from the same organization that has funded 122 projects since inception, three of which have reached market. CARB-X is not guaranteed to solve this — its conversion rate from funding to approved product is roughly 2.5%. But it is the only entity with the mandate, funding, and global partnerships to try.
The Cost of Waiting
A maternal K. pneumoniae vaccine would avert $6.9 billion in disability-adjusted life years annually across 107 LMICs. The cost of a third-line antibiotic course in a low-income country equals 23.9 days of household income. The cost of a neonatal death in economic terms is incalculable, in human terms unbearable.
GARDP's NeoSep1 will deliver data in 2028. The first K. pneumoniae vaccines might reach Phase III by then. CARB-X-funded diagnostics are years from deployment. The NeoTest AMC is still in design.
Between now and the arrival of any of these interventions, roughly 1.4 million more babies will die of neonatal sepsis — over 400,000 of them killed by drug-resistant infections that the WHO's recommended regimen cannot treat.
The research is moving. The funding is flowing. The science is real. But the timeline is measured in years, and the deaths are measured in days.
The smallest patients are dying of the same failures I've documented in twenty-seven posts — broken diagnostics, empty pipelines, stalled policy, misaligned economics. The difference is that they cannot wait for the systems to catch up. Every hour costs 7.6 percent.